down arrow

Atossa Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04962H5063
USD
0.76
0.06 (8.48%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.730.77

52 Week

0.551.30
Valuation
Technical
Day's Volume

CASH

708.17 k

Shareholding (Mar 2025)

FII

1.62%

Held by 25 FIIs

DII

85.72%

Held by 16 DIIs

Promoter

0.00%

How big is Atossa Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Atossa Therapeutics, Inc. has a market capitalization of 104.69 million and reported net sales of 0.00 million with a net profit of -26.35 million over the last four quarters. The balance sheet shows shareholder's funds of 71.48 million and total assets of 76.44 million.

As of Jun 18, Atossa Therapeutics, Inc. has a market capitalization of 104.69 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -26.35 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 71.48 million and total assets of 76.44 million.

Read More

What does Atossa Therapeutics, Inc. do?

22-Jun-2025

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for breast cancer and related conditions. It has a market cap of approximately $104.69 million and reported a net loss of $7 million as of March 2025.

Overview: <BR>Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics and delivery methods for breast cancer and other breast conditions, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 104.69 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: -37.71% <BR>Price to Book: 1.60<BR><BR>Contact Details: <BR>Address: 107 Spring St, SEATTLE WA: 98104-1005 <BR>Tel: ['1 206 5880256', '1 516 222-2560'] <BR>Fax: 1 302 6365454 <BR>Website: https://atossatherapeutics.com/

Read More

Who are in the management team of Atossa Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Atossa Therapeutics, Inc.'s management team includes Dr. Steven Quay as Chairman, President, and CEO, with Dr. Shu-Chih Chen on the Board and several Independent Directors: Dr. Stephen Galli, Mr. H. Lawrence Remmel, Mr. Richard Steinhart, and Mr. Gregory Weaver.

As of March 2022, the management team of Atossa Therapeutics, Inc. includes Dr. Steven Quay, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the Board of Directors features Dr. Shu-Chih Chen as a Director, along with several Independent Directors: Dr. Stephen Galli, Mr. H. Lawrence Remmel, Mr. Richard Steinhart, and Mr. Gregory Weaver.

Read More

Is Atossa Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 14, 2016, Atossa Therapeutics, Inc. is considered overvalued with negative financial metrics, including a Price to Book Value of 1.78 and a ROCE of -2805.50%, indicating significant deterioration in its valuation outlook compared to peers.

As of 14 November 2016, Atossa Therapeutics, Inc. has moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently considered overvalued given its negative financial metrics, including a Price to Book Value of 1.78 and an alarming ROCE of -2805.50%. The EV to EBIT and EV to EBITDA ratios are both at -1.82, further underscoring the company's financial struggles.<BR><BR>When compared to its peers, Atossa's valuation metrics are concerning. For instance, Eton Pharmaceuticals, Inc. has a P/E ratio of -92.8956, while Abeona Therapeutics, Inc. shows a P/E of -4.5154. These comparisons highlight that Atossa is not only underperforming but also lacks a clear path to profitability, as evidenced by its negative returns over various time frames, including a YTD decline of -15.29% compared to the S&P 500's positive return of 2.44%. Overall, Atossa Therapeutics, Inc. appears to be overvalued in the current market environment.

Read More

Is Atossa Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Atossa Therapeutics, Inc. is in a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators show mild bullishness, and it has underperformed the S&P 500 with a 1-year return of -38.04%.

As of 11 September 2025, the technical trend for Atossa Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and Dow Theory show a mildly bullish signal. However, the monthly indicators are mixed, with Bollinger Bands and KST suggesting a bearish outlook. <BR><BR>In terms of performance, Atossa has underperformed the S&P 500 across multiple periods, with a 1-year return of -38.04% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 104 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.00

stock-summary
Return on Equity

-46.81%

stock-summary
Price to Book

1.81

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.35%
0%
-1.35%
6 Months
-10.88%
0%
-10.88%
1 Year
-38.25%
0%
-38.25%
2 Years
-0.04%
0%
-0.04%
3 Years
-0.76%
0%
-0.76%
4 Years
-60.65%
0%
-60.65%
5 Years
-49.7%
0%
-49.7%

Atossa Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Atossa Therapeutics, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Atossa Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and Dow Theory show a mildly bullish signal. However, the monthly indicators are mixed, with Bollinger Bands and KST suggesting a bearish outlook. In terms of performance, Atossa has underperformed the S&P 500 across multiple periods, with a 1-year return of -38.04% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-180.82%
EBIT to Interest (avg)
-22.75
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
26.57%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.78
EV to EBIT
-1.82
EV to EBITDA
-1.82
EV to Capital Employed
51.04
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2805.50%
ROE (Latest)
-37.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 16 Schemes (12.65%)

Foreign Institutions

Held by 25 Foreign Institutions (1.62%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -40.00% vs 38.78% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.00",
          "val2": "-7.10",
          "chgp": "-26.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.40",
          "val2": "-6.00",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 15.28% vs -11.48% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.60",
          "val2": "-31.40",
          "chgp": "12.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.70",
          "val2": "-3.00",
          "chgp": "43.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.50",
          "val2": "-30.10",
          "chgp": "15.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.00
-7.10
-26.76%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.40
-6.00
-40.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -40.00% vs 38.78% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-27.60
-31.40
12.10%
Interest
0.00
0.00
Exceptional Items
-1.70
-3.00
43.33%
Consolidate Net Profit
-25.50
-30.10
15.28%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 15.28% vs -11.48% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Atossa Therapeutics, Inc. stock-summary
stock-summary
Atossa Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).
Company Coordinates stock-summary
Company Details
107 Spring St , SEATTLE WA : 98104-1005
stock-summary
Tel: 1 206 58802561 516 222-2560
stock-summary
https://atossatherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."